Antitumor activity of anti-DLL4 antibodies

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody, Health Informer, August 7, 2009. Subtitle: Targeting Cancer Stem Cells Dramatically Reduces Tumor Growth and Recurrence in Preclinical Models. First paragraph:

OncoMed Pharmaceuticals, Inc. announced the publication in Cell Stem Cell of data demonstrating potent anti-cancer activity in colon and breast cancer models for the company’s first product candidate, OMP-21M18, underlining the therapeutic potential of targeting cancer stem cells to treat solid tumors. OMP-21M18 is currently in Phase 1 clinical testing.

The publication: DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency by Timothy Hoey and 14 co-authors, including Michael F Clarke, John Lewicki and Austin Gurney, Cell Stem Cell 2009(Aug 7); 5(2): 168-77. [PubMed Citation][FriendFeed entry].[Full text of this "Featured Article", via Gratis OA][Full text PDF].

Examples of other links to the News Release: [OncoMed.com (PDF)][Medical News Today][Genetic Engineering & Biotechnology News].